Dr. Scott Pollack – IDO Inhibitors and their Pharmacological Effects

In conjunction with his presentation at the London Excel at ELRIG Drug Discovery 2018, Dr. Scott Pollack, Associate Director of Biophysics and Enzymology at Sygnature Discovery, was asked:

“What are IDO inhibitors and how do you assess their pharmacological effects?”

Latest News

View All

Sygnature Discovery boosts growth of its In…

Sygnature Discovery Appoints New Chief Commercial Officer…

Sygnature Discovery appoints Rick Davies to spearhead…

Sygnature Discovery has Chosen Elsevier as New…